These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37114129)

  • 21. CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
    Montresor A; Toffali L; Rigo A; Ferrarini I; Vinante F; Laudanna C
    Oncotarget; 2018 Oct; 9(80):35123-35140. PubMed ID: 30416684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment.
    Severin F; Frezzato F; Visentin A; Martini V; Trimarco V; Carraro S; Tibaldi E; Brunati AM; Piazza F; Semenzato G; Facco M; Trentin L
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
    Hanna BS; Yazdanparast H; Demerdash Y; Roessner PM; Schulz R; Lichter P; Stilgenbauer S; Seiffert M
    Haematologica; 2021 Apr; 106(4):968-977. PubMed ID: 32139435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells.
    Spaner DE; Shi Y; White D; Mena J; Hammond C; Tomic J; He L; Tomai MA; Miller RL; Booth J; Radvanyi L
    Leukemia; 2006 Feb; 20(2):286-95. PubMed ID: 16341037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia.
    Giménez N; Schulz R; Higashi M; Aymerich M; Villamor N; Delgado J; Juan M; López-Guerra M; Campo E; Rosich L; Seiffert M; Colomer D
    Leukemia; 2020 Jan; 34(1):100-114. PubMed ID: 31197259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
    Lu K; Fang XS; Feng LL; Jiang YJ; Zhou XX; Liu X; Li PP; Chen N; Ding M; Wang N; Zhang J; Wang X
    Cancer Lett; 2015 Apr; 359(2):250-8. PubMed ID: 25636517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity.
    Tomic J; White D; Shi Y; Mena J; Hammond C; He L; Miller RL; Spaner DE
    J Immunol; 2006 Mar; 176(6):3830-9. PubMed ID: 16517754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation.
    Rozková D; Novotná L; Pytlík R; Hochová I; Kozák T; Bartůnková J; Spísek R
    Int J Cancer; 2010 Mar; 126(5):1132-43. PubMed ID: 19685493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
    Slinger E; Thijssen R; Kater AP; Eldering E
    Leukemia; 2017 Dec; 31(12):2601-2607. PubMed ID: 28462919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.
    Liang X; Moseman EA; Farrar MA; Bachanova V; Weisdorf DJ; Blazar BR; Chen W
    Blood; 2010 Jun; 115(24):5041-52. PubMed ID: 20339095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.
    Spaner DE; Masellis A
    Leukemia; 2007 Jan; 21(1):53-60. PubMed ID: 17066089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
    Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
    Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
    Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
    Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
    Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1.
    Battle TE; Frank DA
    Blood; 2003 Oct; 102(8):3016-24. PubMed ID: 12855573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.